

Sneak Peek

Process Scale-up & Tech Transfer for Injectables



Dr. Laura Buttafoco

Protea,
CEO




SYMMETRIC


Road to Success

01

- Build in success from the start (e.g. containment, robust process, automation);
- Control quality from start to finish (in raw materials and operators too);
- Excellent teamwork between different disciplines;
- People (train, lead by example, walk the talk);
- Excel at managing risks proactively.



Impact on Post-Approval Changes




Control Strategy Implementation Options

- ▶ Level 1: **flexible** input material attributes and process parameters; **real-time automatic controls** assure that CQAs consistently conform to the established acceptance criteria
- ▶ Level 2: flexible material attributes and process parameters **within** the established design space
- ▶ Level 3: **any significant change** in these MAs and PPs warrants regulatory oversight

Yu, et al. *Understanding Pharmaceutical Quality by Design*, The AAPS Journal, 2014, 16(4): 771-783

FMEA Approach




Tech Transfer: When & Why

- ▶ From R&D to large scale production;
- ▶ From site to site;
- ▶ Capacity harmonisation or optimisation;
- ▶ Site area changes;
- ▶ Productivity or financial efficiency of the site/company.



At any stage of the lifecycle!!

Technology Transfer Stages




Stages	Initiation	Planning	Knowledge transfer	Readiness	Execution	Handover
Purposes	Identify site with risk profile meeting business objective	Form TT team & assess risk	Identify elements critical to knowledge transfer and timing	Activities & deliverables tracking	RU qualifies process at scale & regulatory submission	Close TT with regulatory approval & normal operations

Mathematical Models for Mixing Scale Up




3D CAD Model of Bag, Dip Tube and Jet mixer




Jet mixer

3D View of Jet mixer



Cross-sectional View of Jet mixer



Impeller

Note: This 3D CAD model was created by Griffin based upon the 2D drawings.

EMA vs FDA Guidance



FDA		EMA		
PV Guideline Jan 2011 (Submission and GMP)		Annex 15 Mar 2011 (GMP)	PV drug product Feb 2014 (Submission)	PV Biotech API Apr 2016 (Submission)
Stage 1	Process Design (Process understanding and strategy for process control)	Ref: ICH Q8, 9, 10, 11, CQA, CPP, Control Strategy	Ref: ICH Q11, enhanced or traditional sampling	Ref: ICH Q11, enhanced or traditional sampling
Stage 2	Process Qualification: 2a (Equipment/ Utility) + 2b (Process Performance Qualification). Confirm Stage 1. Justify no of batches	URS, DQ, FAT, SAT, IQ, OQ, PQ	ANNEX 15	ANNEX 15
		PV (traditional, continuous approach, hybrid) If traditional, min 3 batches	PV (traditional, continuous approach, hybrid) If traditional, min 3 batches	PV (Process Evaluation and verification). An 'appropriate' no of batches
Stage 3	Continued Process Verification (CPV)	Ongoing Process Verification	Ongoing Process Verification	Ongoing Process Verification



+421 2/222 001 66



info@symmetric.events

Register

Registration

Sneak Peek

*Process Scale-up & Tech Transfer
for Injectables*



**CLICK
HERE TO**



Mliekarenská 9, 821 09
Bratislava, Slovak Republic
ID: 47 068 124
VAT no: SK2023741973
Office: +421 948 262 346

 **100% Secure payments**

Your details are protected and safe with us. Taxes calculated at the checkout.

